Philip S. Low PhD

Dr. Philip Low is the Presidential Scholar for Drug Discovery and the RC Corley Distinguished Professor of Chemistry at Purdue University, where he directs a lab of 35 graduate students/postdocs and 50 undergraduate researchers. Dr. Low has devoted 45 years to designing novel imaging and therapeutic agents for the diagnosis and treatment of human diseases. Low has co-founded 7 companies (Endocyte, OnTarget Laboratories, Umoja Biopharma, Morphimmune, Novosteo, Eradivir, and ErythroCure) to commercialize his discoveries and has recently formed and funded the Low Institute for Therapeutics (LIFT) to accelerate the transfer of his most promising discoveries into human clinical trials. In recognition of his contributions, Low has been recognized with multiple national and international awards, including the American Association for Cancer Research’s Award for Chemistry in Cancer Research, the American Chemical Society’s Award for Cancer Research (Sosnovsky Award), the American Chemical Society’s Award for Chemistry in the Public Interest (Esselen Award), the Alfred Burger Award in Medicinal Chemistry, the National Academy of Inventors, the American Lung Associations Legacy Award and an NIH MERIT Award. Dr. Low received his B.S. in Chemistry from BYU (1971) and his Ph.D. in Biochemistry from UCSD (1975).